Profile picture

Professor Carolyn S P Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)
Membership: FESC Member HFA Member
Follow
Biography
Dr Lam is recognized globally for expertise in heart failure with mildly reduced and preserved ejection fraction. She is a world-renown clinical trialist, contributing in global leadership capacity to several heart failure trials that have changed practice in the field. Dr. Lam’s leadership in the field is recognized in her appointment to the 2021 ESC Heart Failure Guidelines Task Force and as International Honorary Fellow of the Heart Failure Society of America 2021. Her accomplishments are also recognized in numerous awards and grants: She is a recipient of the NMRC Senior Investigator Clinician Scientist Award, Founding Programme Lead of A*STaR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), a Clarivate Highly Cited Researcher 2021 in Clinical Medicine and lead author of the chapter on HFpEF for Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Edition. She serves as Associate Editor for Circulation and Eur J Heart Fail.
Logo ESC

Contributor content

Clinical translation of GLP-1RAs for adiposity-driven HFpEF: from guidelines to practice
Session
Clinical translation of GLP-1RAs for adiposity-driven HFpEF: from guidelines to practice
30 August 2026
From guidelines to clinical impact: what are the missing pieces to successful guideline-directed medical therapy implementation?
Session
From guidelines to clinical impact: what are the missing pieces to successful guideline-directed medical therapy implementation?
30 August 2026
Building better outcomes: advancing guideline-directed outpatient care in heart failure
Session
Building better outcomes: advancing guideline-directed outpatient care in heart failure
29 August 2026
Why your heart failure patient still isn’t improving: residual risk and the cardiorenal gap
Session
Why your heart failure patient still isn’t improving: residual risk and the cardiorenal gap
28 August 2026
The HFrEF medication toolkit for patients who need more: from evidence to implementation
Session
The HFrEF medication toolkit for patients who need more: from evidence to implementation
9 May 2026
GLP-1RAs in obesity-related HFpEF: a new era in treatment
Session
GLP-1RAs in obesity-related HFpEF: a new era in treatment
31 August 2025
Cardiometabolic patient in 2025: the challenges of control & adherence
Session
Cardiometabolic patient in 2025: the challenges of control & adherence
30 August 2025
HOT LINE 2
Session
HOT LINE 2
30 August 2025
No time to lose: timely use of SGLT2 inhibitors for heart failure in the hospital
Session
No time to lose: timely use of SGLT2 inhibitors for heart failure in the hospital
29 August 2025
Revolutionising thrombosis treatment in acute coronary syndrome (ACS), secondary stroke prevention (SSP) and atrial fibrillation (AF): bridging the gaps with next generation anticoagulation strategies
Session
Revolutionising thrombosis treatment in acute coronary syndrome (ACS), secondary stroke prevention (SSP) and atrial fibrillation (AF): bridging the gaps with next generation anticoagulation strategies
29 August 2025